Jane Street Group LLC Has $26,000 Holdings in Rallybio Co. (NASDAQ:RLYB)

Jane Street Group LLC trimmed its holdings in Rallybio Co. (NASDAQ:RLYB) by 58.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,275 shares of the company’s stock after selling 30,805 shares during the period. Jane Street Group LLC owned about 0.05% of Rallybio worth $26,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of RLYB. Hsbc Holdings PLC bought a new position in shares of Rallybio during the 2nd quarter valued at about $25,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Rallybio during the 2nd quarter worth approximately $61,000. Acadian Asset Management LLC lifted its stake in Rallybio by 116.3% in the second quarter. Acadian Asset Management LLC now owns 67,695 shares of the company’s stock valued at $89,000 after buying an additional 36,401 shares in the last quarter. Almitas Capital LLC acquired a new position in shares of Rallybio in the second quarter valued at approximately $135,000. Finally, FMR LLC increased its position in shares of Rallybio by 1.1% during the third quarter. FMR LLC now owns 2,315,480 shares of the company’s stock worth $2,709,000 after acquiring an additional 25,422 shares in the last quarter. 90.34% of the stock is currently owned by institutional investors.

Rallybio Stock Performance

NASDAQ RLYB opened at $0.89 on Friday. The stock has a market capitalization of $36.92 million, a price-to-earnings ratio of -0.56 and a beta of -1.48. Rallybio Co. has a 52 week low of $0.84 and a 52 week high of $3.46. The stock’s 50 day moving average price is $1.02 and its two-hundred day moving average price is $1.11.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Rallybio in a research report on Monday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Rallybio currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.75.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.